Whitfield Represents AbbVie on Acquisition of Allergan for $63 Billion
Overview
The source reports Abb Vie’s agreement to acquire Allergan through a cash-and-share transaction.
Transaction value
The announcement gives an equity value of approximately $63 billion, rather than treating that amount as an enterprise valuation.
Business combination
It describes a combined pharmaceutical portfolio spanning immunology, oncology, aesthetics, neuroscience, women’s health, eye care and virology.
Announcement status
The article originally anticipated an early 2020 close subject to regulatory approvals. Eric Schiele, Jonathan Davis and Carlo Zenkner are identified among corporate leads, with additional finance, compensation, competition, tax and healthcare specialists listed in the source.
